Monopar Therapeutics Inc
4.57 - 4.9399
4.28 - 17.01
Join Discuss about MNPR with like-minded investors
Next Dividend Date
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stagepreclinical antibody, MNPR-101, for advanced cancers and severe COVID-19.
HQ: 1000 Skokie Blvd Ste 350 Wilmette, 60091-1146 Illinois